The effects of Olmesartan/amlodipine administered in the Morning or At Night on nocturnal blood pressure reduction in Chinese patients with mild-moderate essential hypertension (OMAN Trial): study protocol for a prospective, multicenter, randomized, open-label clinical trial {1}

Wang Z, Chen Z, Zhang L, Wang X, Hao G, Zhang Z, Shao L, Tian Y, Dong Y, Zheng C, et al. Status of hypertension in China: results from the China hypertension survey, 2012–2015. Circulation. 2018;137(22):2344–56.

Article  PubMed  Google Scholar 

Zhou M, Wang H, Zeng X, Yin P, Zhu J, Chen W, Li X, Wang L, Wang L, Liu Y, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2019;394(10204):1145–58.

Article  PubMed  PubMed Central  Google Scholar 

Lu J, Lu Y, Wang X, Li X, Linderman GC, Wu C, Cheng X, Mu L, Zhang H, Liu J, et al. Prevalence, awareness, treatment, and control of hypertension in China: data from 1·7 million adults in a population-based screening study (China PEACE Million Persons Project). Lancet. 2017;390(10112):2549–58.

Article  PubMed  Google Scholar 

Parati G, Kjeldsen S, Coca A, Cushman WC, Wang J. Adherence to single-pill versus free-equivalent combination therapy in hypertension: a systematic review and meta-analysis. Hypertension. 2021;77(2):692–705.

Article  CAS  PubMed  Google Scholar 

Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, Ramirez A, Schlaich M, Stergiou GS, Tomaszewski M, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75(6):1334–57.

Article  CAS  PubMed  Google Scholar 

Chrysant SG, Melino M, Karki S, Lee J, Heyrman R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther. 2008;30(4):587–604.

Article  CAS  PubMed  Google Scholar 

Zhu J-R, Zhang S-Y, Gao P-J. Efficacy and safety of olmesartan medoxomil/amlodipine fixed-dose combination for hypertensive patients uncontrolled with monotherapy. Arch Pharm Res. 2014;37(12):1588–98.

Article  CAS  PubMed  Google Scholar 

Tadic M, Cuspidi C, Grassi G, Mancia G. Isolated nocturnal hypertension: what do we know and what can we do? Integr Blood Press Control. 2020;13:63–9.

Article  PubMed  PubMed Central  Google Scholar 

Cuspidi C, Facchetti R, Bombelli M, Sala C, Tadic M, Grassi G, Mancia G. Is night-time hypertension worse than daytime hypertension? A study on cardiac damage in a general population: the PAMELA study. J Hypertens. 2017;35(3):506–12.

Article  CAS  PubMed  Google Scholar 

Androulakis E, Papageorgiou N, Chatzistamatiou E, Kallikazaros I, Stefanadis C, Tousoulis D. Improving the detection of preclinical organ damage in newly diagnosed hypertension: nocturnal hypertension versus non-dipping pattern. J Hum Hypertens. 2015;29(11):689–95.

Article  CAS  PubMed  Google Scholar 

Ogedegbe G, Spruill TM, Sarpong DF, Agyemang C, Chaplin W, Pastva A, Martins D, Ravenell J, Pickering TG. Correlates of isolated nocturnal hypertension and target organ damage in a population-based cohort of African Americans: the Jackson Heart Study. Am J Hypertens. 2013;26(8):1011–6.

Article  PubMed  PubMed Central  Google Scholar 

Wang C, Deng W-J, Gong W-Y, Zhang J, Zhang Q-Z, Ye ZC, Lou T. Nocturnal hypertension correlates better with target organ damage in patients with chronic kidney disease than a nondipping pattern. J Clin Hypertens (Greenwich). 2015;17(10):792–801.

Article  PubMed  Google Scholar 

Boggia J, Li Y, Thijs L, Hansen TW, Kikuya M, Björklund-Bodegård K, Richart T, Ohkubo T, Kuznetsova T, Torp-Pedersen C, et al. Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet. 2007;370(9594):1219–29.

Article  PubMed  Google Scholar 

Yang W-Y, Melgarejo JD, Thijs L, Zhang Z-Y, Boggia J, Wei F-F, Hansen TW, Asayama K, Ohkubo T, Jeppesen J, et al. Association of office and ambulatory blood pressure with mortality and cardiovascular outcomes. JAMA. 2019;322(5):409–20.

Article  PubMed  PubMed Central  Google Scholar 

Hermida RC, Crespo JJ, Domínguez-Sardiña M, Otero A, Moyá A, Ríos MT, Sineiro E, Castiñeira MC, Callejas PA, Pousa L, et al. Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial. Eur Heart J. 2020;41(48):4565–76.

Article  CAS  PubMed  Google Scholar 

Poulter NR, Savopoulos C, Anjum A, Apostolopoulou M, Chapman N, Cross M, Falaschetti E, Fotiadis S, James RM, Kanellos I, et al. Randomized crossover trial of the impact of morning or evening dosing of antihypertensive agents on 24-hour ambulatory blood pressure. Hypertension. 2018;72(4):870–3.

Article  CAS  PubMed  Google Scholar 

Thoonkuzhy C, Rahman M. New insights on chronotherapy in hypertension: is timing everything? Curr Hypertens Rep. 2020;22(4):32.

Article  PubMed  Google Scholar 

Zhao P, Xu P, Wan C, Wang Z. Evening versus morning dosing regimen drug therapy for hypertension. Cochrane Database Syst Rev. 2011;2011(10):CD004184.

Kario K, Shin J, Chen C-H, Buranakitjaroen P, Chia Y-C, Divinagracia R, Nailes J, Hoshide S, Siddique S, Sison J, et al. Expert panel consensus recommendations for ambulatory blood pressure monitoring in Asia: The HOPE Asia Network. J Clin Hypertens (Greenwich). 2019;21(9):1250–83.

Article  PubMed  Google Scholar 

Wang K-L, Yu W-C, Lu T-M, Chen L-C, Leu H-B, Chiang C-E. Amlodipine/valsartan fixed-dose combination treatment in the management of hypertension: a double-blind, randomized trial. J Chin Med Assoc. 2020;83(10):900–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kario K, Hoshide S, Chia Y-C, Buranakitjaroen P, Siddique S, Shin J, Turana Y, Park S, Tsoi K, Chen C-H, et al. Guidance on ambulatory blood pressure monitoring: a statement from the HOPE Asia Network. J Clin Hypertens (Greenwich). 2021;23(3):411–21.

Article  PubMed  Google Scholar 

Mackenzie IS, Rogers A, Poulter NR, Williams B, Brown MJ, Webb DJ, Ford I, Rorie DA, Guthrie G, Grieve JWK, et al. Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial. Lancet. 2022;400(10361):1417–25.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Scott LJ, McCormack PL. Olmesartan medoxomil: a review of its use in the management of hypertension. Drugs. 2008;68(9):1239–72.

Article  CAS  PubMed  Google Scholar 

Li X, Mo E, Chen L. Pharmacokinetics and bioequivalence evaluation of 2 olmesartan medoxomil and amlodipine besylate fixed-dose combination tablets in healthy Chinese volunteers under fasting and fed conditions. Clin Pharmacol Drug Dev. 2022;11(6):761–9.

Article  CAS  PubMed  Google Scholar 

Haria M, Wagstaff AJ. Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs. 1995;50(3):560–86.

Article  CAS  PubMed  Google Scholar 

留言 (0)

沒有登入
gif